ReviewCommunications medicine2026
The role of hepatocyte epigenetics in the pathogenesis of metabolic dysfunction-associated steatotic liver disease.
Review in Communications medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Betaine in Metabolic Dysfunction-Associated Steatotic Liver Disease: Mechanisms of Action and Therapeutic Potential.Antioxidants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide, and it can progress to cirrhosis and hepatocellular carcinoma (HCC). Genetic susceptibility, the gut microbiota, changes in hepatic metabolic pathways, the regulation of lipid metabolism pathways, cellular interactions in the liver, and epigenetic modifications all significantly contribute to MASLD pathogenesis. Recently, epigenetic changes involved in the development and occurrence of MASLD have garnered increasing attention. However, current epigenetic research predominantly focuses on the serum or liver at the whole-tissue level. Consequently, the epigenetic regulation within specific liver cell types, particularly hepatocytes, remains unclear, and its precise mechanisms are not fully understood. This article discusses in detail the specific epigenetic regulatory mechanism of hepatocytes during the occurrence of MASLD, as well as possible therapeutic targets and therapies for these modifications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.